A 36-Month Study on the Cost/Utility of Add-On Omalizumab in Persistent Difficult-to-Treat Atopic Asthma in Italy

References

• Bousquet J, Dahl R, Khaltaev N. Global alliance against chronic respiratory diseases. Eur Respir J 2007; 29:233–239.
   PubMed Web of Science ®Google Scholar
• Adcock IM, Caramori G, Chung KF. New targets for drug development in asthma. Lancet 2008; 372:1073–1087.
   PubMed Web of Science ®Google Scholar
• Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children (Cochrane Review). The Cochrane Library Issue. Vol 2. Chichester: Wiley, 2005.
   Google Scholar
• FDA Omalizumab Product Approval Information Sheet 20-06-2003.
   Google Scholar
• Niven R, Chung KF, Panahloo Z, Blogg M, Ayre G. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study. Respir Med 2008; 102: 1371–1378.
   PubMed Web of Science ®Google Scholar
• Solèr M, Matz J, Townley R, Buhl R, O’Brien J, Fox H, Thirlwell J, Gupta N, Della Cioppa G. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18:254–261.
   PubMed Web of Science ®Google Scholar
• Busse WW. Anti-immunoglobulin E (omalizumab) therapy in allergic asthma. Am J Respir Crit Care Med 2001; 164:S12–S17.
   PubMed Web of Science ®Google Scholar
• Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M, Fox H, Surrey K. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004; 59:709–717.
   PubMed Web of Science ®Google Scholar
• Diukanovic R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, Bao W, Fowler-Taylor A, Matthews J, Busse WW, Holgate ST, Fahy JV. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004; 170:583–593.
   PubMed Web of Science ®Google Scholar
• Ayers JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004; 59: 701–708.
   PubMed Web of Science ®Google Scholar
• Holgate ST, Chuchalin AG, Hébert J, Lötvall J, Persson GB, Chung KF, Bousquet J, Kerstjens HA, Fox H, Thirlwell J, Cioppa GD. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004; 34:632–638.
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayers J, Slavin R, Hébert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60:309–316.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, Rosen KE, Eisner MD, Wong DA, Busse W. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 2011; 154(9):573–582.
   PubMed Web of Science ®Google Scholar
• Dal Negro RW, Pradelli L, Tognella S, Micheletto C, Iannazzo S. Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy. Eur Ann Allergy Clin Immunol. 2011; 43(2):45–53.
   PubMedGoogle Scholar
• Tognella S, Dal Negro RW. Omalizumab: una risposta terapeutico-gestionale per il controllo dell’asma grave resistente. It J Chest Dis 2007; 61:390–394.
   Google Scholar
• Regional DRG Tariffs. Aggiornamento del tariffario per la remunerazione delle prestazioni di assistenza Ospedaliera. Regione Veneto. Deliberazione della Giunta n. 916 del 28-03-2006.
   Google Scholar
• Regional Specialist Tariffs. Nomenclatore Tariffario Regionale delle prestazioni di assistenza specialistica ambulatoriale: aggiornamento tariffe di cui alla D.G.R. n.61 del 21-01-05. Regione Veneto. Deliberazione della Giunta n. 917 del 28-03-2006.
   Google Scholar
• Garattini L, Castelnuovo E, Lanzeni D, Viscarra C. Durata e costo delle visite in medicina generale: il progetto DYSCO. Farmeconomia e percorsi terapeutici 2003; 4(2):109–114.
   Google Scholar
• Italian Drugs Formulary. Informatore Farmaceutico—68a edizione 2008. Elsevier Masson, 2008.
   Google Scholar
• Off-Patent Drugs Reference Price System. Lista di trasparenza dei medicinali inseriti nell’elenco dei farmaci equivalenti (Legge 178/2002) con i relativi prezzi di riferimento aggiornati a giugno 2011. Available at: http://www.agenziafarmaco.gov.it/it/content/liste-di- trasparenza-e-rimborsabilita. Accessed September, 2011.
   Google Scholar
• National Hospital Discharge Database. Statistiche sui ricoveri ospedalieri. Available at: http://www.ministerosalute.it/programmazione/sdo/ric_informazioni/default.jsp. Accessed December, 2008.
   Google Scholar
• Ståhl E, Lindberg A, Jansson SA, Rönmark E, Svensson K, Andersson F, Löfdahl CG, Lundbäck B. Health-related quality of life is related to COPD disease severity. Health Qual Life Outcomes 2005; 3:56.
   PubMedGoogle Scholar
• Oba Y. Cost-effectiveness of long-acting bronchodilators for chronic obstructive pulmonary disease. Mayo Clin Proc 2007; 82(5):575–582.
   PubMed Web of Science ®Google Scholar
• Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000; 20(3):332–342.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004; 125(4):1378–1386.
   PubMed Web of Science ®Google Scholar